Dihexa & Cerebrolysin: advanced cognitive peptides, honestly assessed

TL;DR

• The evidence ladder runs backwards from the reputation ladder - the compound with the strongest reputation in this category has the weakest evidence behind it.
• Dihexa has no published human trial data - no Phase 1 safety study and no human pharmacokinetics; every cognition finding comes from rodent and zebrafish models.
• The 2014 HGF/c-Met mechanism paper was retracted in April 2025 after a Washington State University investigation found falsified and/or fabricated figures; a companion paper has carried an Expression of Concern since 2021.
• c-Met is an oncogenic pathway, so a compound proposed to activate it with no human safety data warrants more caution than the category's casual reputation suggests.
• Cerebrolysin's large human trial base keeps not converging - a Cochrane review of six RCTs (597 participants) in vascular dementia found insufficient evidence for routine use, while an independent meta-analysis of 14 stroke RCTs reported a mean NIHSS improvement of about 1.39 points.
• Both are investigational and neither is FDA-approved for cognitive enhancement; dihexa acetate is one of five substances the PCAC will consider when it reconvenes before the end of February 2027 - a procedural fact, not an evidence signal.

Educational content, not medical advice. No doses or protocols appear; any use is physician-directed. Both compounds are investigational and neither is FDA-approved for cognitive enhancement.

Updated September 2026: corrects the regulatory section, which stated that neither compound was on an FDA compounding docket. Dihexa acetate is one of five substances the FDA has said the Pharmacy Compounding Advisory Committee will consider when it reconvenes before the end of February 2027. The evidence assessment is unchanged: a docket nomination is a procedural fact, not an evidence signal.

---

The nootropic-peptide category has a clear ladder in the popular imagination. Semax and Selank sit at the bottom as the accessible entry point. Dihexa and Cerebrolysin sit at the top, described in forums as the serious, potent options - the ones you graduate to.

The evidence ladder runs almost exactly backwards. Semax and Selank have real, if regional, randomized human data. Cerebrolysin has an enormous human trial literature that systematic reviewers keep declining to endorse. Dihexa has none - and its most-cited mechanism paper was retracted for fabricated data. Reputation in this corner of the market is built on potency claims, not on published results.

Where these sit versus Semax and Selank

The pattern worth noticing: the compound with the strongest reputation has the weakest evidence.

Dihexa - the synaptogenesis story, and what happened to it

Dihexa is a metabolically stabilized analog of angiotensin IV, developed at Washington State University. The claim that made it famous is striking: that it promotes synaptogenesis - the formation of new synaptic connections - by acting on the hepatocyte growth factor (HGF) / c-Met signalling system, and that it does so at orders of magnitude greater potency than BDNF.

Two things need saying plainly.

First, the human data does not exist. As of 2026, searches of PubMed and ClinicalTrials.gov return no completed or ongoing human clinical trials of dihexa for any indication. No published Phase 1 safety study. No human pharmacokinetics - meaning nobody has published what dose reaches the brain, how long it stays, or how it is cleared. Every cognition finding comes from rodent and zebrafish models, principally the restoration of learning in scopolamine-impaired and aged rats.

Second, the mechanism evidence has been formally compromised. The 2014 paper that provided the primary evidence for the HGF/c-Met binding mechanism was retracted in April 2025, after a Washington State University investigation concluded the figures contained falsified and/or fabricated data. A further paper from the same lab has carried an Expression of Concern since 2021.

Retraction does not prove dihexa is inert. Compounds can work through mechanisms other than the one their discoverers claimed, and the behavioural rodent findings were reported by multiple groups. But it does mean the specific, confident mechanistic story sold in marketing copy - "it's a potent HGF/c-Met agonist that builds synapses" - currently rests on withdrawn evidence. That is a materially different situation from "early but promising," and most vendor pages have not updated to reflect it.

There is also an unresolved theoretical concern that follows directly from the mechanism claim: c-Met is an oncogenic pathway. A compound proposed to activate it, with no human safety data, warrants more caution than the category's casual reputation suggests.

Cerebrolysin - a large evidence base that keeps not converging

Cerebrolysin is a different kind of compound and a different kind of problem. It is not a single peptide but a porcine-brain-derived mixture of low-molecular-weight peptides and free amino acids, administered intravenously or intramuscularly, and it has been used clinically in parts of Europe and Asia for decades. Unlike dihexa, it has been studied in humans extensively.

The difficulty is what those studies show.

• Vascular dementia. A Cochrane review pooling six randomized trials (597 participants) found improvements in cognition and global clinical impression - but flagged follow-up of six months or less, small samples, and heterogeneous outcome reporting, and concluded there was insufficient evidence to recommend it as routine treatment. Cochrane's updated position notes that no new vascular-dementia trials have appeared since, that promotion has continued regardless, and that if a benefit exists it may be too small to be clinically meaningful.
• Acute ischemic stroke. Cochrane reviews have concluded no clear benefit on mortality or disability, with risk-of-bias concerns across many included trials. More recent independent meta-analyses are more favourable - a pooled analysis of 14 randomized trials reported a mean NIHSS improvement of about 1.39 points - and safety meta-analyses across twelve trials have not flagged excess adverse events. So the picture is genuinely mixed rather than simply negative.

Two structural problems keep this literature from resolving. Because Cerebrolysin is a biological mixture rather than a defined molecule, batch-to-batch composition is hard to standardize, which complicates replication. And a large share of the trial base comes from regions and sponsors with recognized publication-bias concerns.

The honest summary: Cerebrolysin has a plausible neurotrophic rationale, a real and sizeable human trial record, decades of clinical use, and no clear demonstration of clinically meaningful benefit in the indications most rigorously reviewed. None of that research is about cognitive enhancement in healthy people - it is about recovery in damaged brains, which is a different question entirely.

The hype gap - and why it runs this direction

Every compound in this category is sold on the same implicit logic: less regulated means more powerful, and thinner evidence means the establishment hasn't caught up yet. The evidence supports the opposite reading. Thin evidence is usually just thin evidence.

Three specific gaps are worth naming.

• Animal-to-human translation is poor for neurotrophic compounds. The graveyard of failed neurotrophic drug programs is large, and rodent cognitive restoration has repeatedly failed to translate.
• "Repair" data is being read as "enhancement" data. Cerebrolysin's trials are in stroke and dementia patients. Dihexa's rodent work is in impaired and aged animals. Neither tells you what happens in a healthy 34-year-old who wants sharper focus. The population question in full - who these trials enrolled, and where the age-stratified data simply does not exist - is worked through in nootropic peptides and the ageing brain.
• Grey-market identity risk compounds everything above. For a research-only compound with no human PK, you are guessing at the dose of a substance you cannot verify is what the label says.
• Reaching the brain is an assumption, not a finding. Every mechanism above presumes delivery into the central nervous system, which is a separate question with its own evidence - see whether nootropic peptides cross the blood-brain barrier.

Who explores them, and with what expectations

Realistically: people with a specific neurological concern who have exhausted better-supported options, and cognitive-optimization readers who have plateaued on fundamentals. For the second group, the honest advice is unglamorous - sleep architecture, cardiovascular fitness, hearing correction, and treated mood disorders have far stronger cognitive evidence than anything in this article.

If someone is going to explore this tier anyway, the sequencing that makes sense is: better-evidenced compounds first, one variable at a time, with a clinician who knows what you are taking. Stacking dihexa and cerebrolysin together - a common forum suggestion - makes any effect and any adverse event uninterpretable, and doubles the sourcing risk. Vivre approaches the whole category through evidence-tiered protocols such as V-02 Focus for memory and mental clarity rather than compound-by-compound experimentation.

Regulatory status and sourcing

Neither compound is FDA-approved in the United States. Cerebrolysin is approved and prescribed in a number of other countries - a genuine distinction from dihexa, though one that reflects differing regulatory standards rather than settled evidence. Dihexa is not legally marketed for human use anywhere and circulates purely as a research chemical.

**Dihexa acetate is, however, on the FDA's second peptide docket. Neither compound featured in the Pharmacy Compounding Advisory Committee's July 2026 session - that meeting covered BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax and Epitalon, and recommended six of the seven, declining Emideltide. The FDA has since stated that the committee will reconvene before the end of February 2027 to consider five further substances, and Dihexa acetate is one of the five** (alongside GHK-Cu, Melanotan II, cathelicidin/LL-37 and pegylated mechano growth factor). Cerebrolysin is not among them.

It is worth being blunt about what that does and does not signal, because the inference readers reach for is the wrong one. A docket nomination is a procedural fact, not an evidence signal. Substances arrive on these dockets because someone nominated them, not because a body reviewed the literature and found it persuasive - and nothing above changes: dihexa still has no published human trial data and still carries a retracted foundational mechanism paper. The ladder runs nominated → reviewed → recommended → listed → available, and dihexa sits on the first rung. Whatever the committee decides, a recommendation is nonbinding, it is not an approval, and the notice-and-comment rulemaking that would have to follow takes twelve months or more. The context is in the 2026 peptide reclassification explainer, the second PCAC peptide docket and which peptides are legal in 2026.

The bottom line

Dihexa and Cerebrolysin are not the advanced tier of nootropic peptides. They are the least resolved tier. Cerebrolysin has earned decades of clinical attention and still cannot produce a clean positive verdict from independent reviewers; dihexa has an interesting hypothesis, no human data, and a retracted foundational paper. Anyone selling either as a straightforward cognitive upgrade is selling ahead of the evidence by a wide margin.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore Semax.

Frequently asked questions

Is dihexa safe? There is no published human safety data - no Phase 1 trial, no human pharmacokinetics. That is not a clean bill of health; it is an absence of information. The proposed mechanism involves the c-Met pathway, which is implicated in cancer biology, so the theoretical concerns are not trivial either.

Does Cerebrolysin work? It depends entirely on the question. For acute ischemic stroke and vascular dementia, it has a large randomized trial base that Cochrane reviewers have repeatedly judged insufficient to recommend routine use, with some more recent independent meta-analyses reporting modest neurological improvement. For cognitive enhancement in healthy people, there is essentially no evidence at all.

Is dihexa stronger than Semax? Potency claims for dihexa come from rodent work and from mechanism papers, one of which was retracted in 2025 for fabricated data. Semax has actual randomized human trials. "Stronger" is not established, and the comparison is being made across very different evidence tiers.

Are these legal? Neither is FDA-approved in the US. Cerebrolysin is an approved prescription product in several other countries; dihexa is not legally marketed for human use and is sold as a research chemical. Status varies by jurisdiction and should be verified locally.

Related reading

• Semax and Selank: a beginner's guide to nootropic peptides · Is Cerebrolysin approved outside the US? - the jurisdiction-by-jurisdiction status, and why the US gap is regulatory rather than a rejection · The 2026 FDA peptide reclassification · Which peptides are legal in 2026 · Peptides for sleep · The honest peptide side-effects guide
• Part of The Guide to Nootropic Peptides (pillar forthcoming - /guide/nootropic-peptides)

---

Educational content, not medical advice. Dihexa has no published human trial data and its principal mechanism paper was retracted in 2025; Cerebrolysin is not FDA-approved in the US and independent systematic reviews have found insufficient evidence for routine use. Physician-directed use and verified product only. Anyone with a history of malignancy, or taking psychiatric or neurological medication, requires specialist oversight. Claims for the Malaysian market are subject to MAB requirements.

References

• Dihexa: metabolically stabilized angiotensin IV analog (Washington State University); rodent and zebrafish cognition data only; no registered or published human trials as of 2026; 2014 HGF/c-Met mechanism paper retracted April 2025 following institutional misconduct finding (falsified/fabricated figures); companion paper under Expression of Concern since 2021. · Cerebrolysin: porcine-brain-derived peptide/amino-acid mixture. Cochrane review (Cui et al., 2019/2013 pooling) - 6 RCTs, 597 participants, vascular dementia: cognitive and global improvement reported but insufficient evidence for routine use; no new vascular-dementia trials since. Cochrane (Ziganshina et al., through 2020), acute ischemic stroke: no clear benefit on death or disability, risk-of-bias concerns. Independent meta-analysis of 14 RCTs: mean NIHSS change +1.39. Safety meta-analysis of 12 RCTs: no excess adverse events. · FDA PCAC July 23–24 2026 docket: BPC-157, KPV, TB-500, MOTS-C (Jul 23); Emideltide/DSIP, Semax, Epitalon (Jul 24) - neither dihexa nor cerebrolysin included.